To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Abroad (travel likely)RecruitingPHASE2

Conditions

Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Universiti Kebangsaan Malaysia, Bandar Tun Razak, Kuala Lumpur, Malaysia
Contact: Study coordinator (S Fadilah Abdul Wahid Dr.) · sfadilah@hctm.ukm.edu.my · +60391456450
Contact: Principal Investigator (S Fadilah Abdul Wahid Dr)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lymphoma

Abroad (travel likely)RecruitingPHASE1

La Jolla, United States · Laguna Hills, United States

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Large B-cell Lymphoma · Lymphoma, B-Cell · Relapsed Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE3

Gilbert, United States · Scottsdale, United States

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Non-hodgkin Lymphoma · Refractory Lymphoma · Chimeric Antigen Receptor T-cell

Abroad (travel likely)RecruitingPHASE1

Xiamen, China

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia · Non-hodgkin Lymphoma

Abroad (travel likely)RecruitingEARLY_PHASE1

Hangzhou, China